EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1

Lior Soday, Chotima Seripracharat, Janine L Gray iD, André F S Luz, Ryan T Howard, Ravi Singh iD, Thomas J Burden iD, Erika Bernardini, Miguel Mateus-Pinheiro, Jens Petersen, Anders Gunnarsson, Jenny Gunnarsson und 14 weitere

ACS Chemical Biology · 2025

DOI: 10.1021/acschembio.5c00112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2025. Verfasst von Lior Soday und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Necroptosis, Protein Kinase Inhibitors, Drug Discovery. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Engineering and Physical Sciences Research Council, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Necroptosis is a form of programmed cell death that, when dysregulated, is associated with cancer and inflammatory and neurodegenerative diseases. Here, starting from hits identified from a phenotypic high-throughput screen for inhibitors of necroptosis, we synthesized a library of compounds containing a 7-phenylquinoline motif and validated their anti-necroptotic activity in a novel live-cell assay. Based on these data, we designed an optimized photoaffinity probe for target engagement studies and through biochemical and cell-based assays established receptor-interacting kinase 1 (RIPK1) as the cellular target, with inhibition of necroptosis arising from the prevention of RIPK1 autophosphorylation and activation. X-ray crystallography and mass spectrometry revealed that these compounds bind at the hinge region of the active conformation of RIPK1, establishing them as type I kinase inhibitors. In addition, we demonstrated in vitro synergy with type III kinase inhibitors, such as necrostatin-1 and found that lead compounds protected mice against acute inflammation in necroptosis models in vivo. Overall, we present a novel pharmacophore for inhibition of human RIPK1, a key protein involved in necroptosis, and provide a photoaffinity probe to explore RIPK1 target engagement in cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesNecroptosisProtein Kinase InhibitorsDrug DiscoveryHumansAnimalsMiceCrystallography, X-RayHigh-Throughput Screening Assays

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K.
  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal.
  • Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • The Francis Crick Institute, London NW1 1AT, U.K.
  • Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • Department of Infectious Diseases, Imperial College London, Flowers Building, South Kensington Campus, London SW7 2AZ, U.K.

ORCID-Profile: Janine L Gray, Ravi Singh, Thomas J Burden, Tove Sjögren, James S Scott, Edward W Tate

Förderung

  • AstraZeneca
  • Engineering and Physical Sciences Research Council
  • Medical Research Council
  • Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa
  • 'la Caixa' Foundation
  • Ministry of Higher Education, Science, Research and Innovation, Thailand

Zitieren

APA

Soday, L., Seripracharat, C., Gray, J. L., Luz, A. F. S., Howard, R. T., Singh, R., Burden, T. J., Bernardini, E., Mateus-Pinheiro, M., Petersen, J., Gunnarsson, A., Gunnarsson, J., Aagaard, A., Sjögren, T., Maslen, S., Bartlett, E. J., Iles, A. F., Smith, D. M., Scott, J. S., …, & Tate, E. W. (2025). Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1. ACS Chemical Biology. https://doi.org/10.1021/acschembio.5c00112

Vancouver

Soday L, Seripracharat C, Gray JL, Luz AFS, Howard RT, Singh R, et al. Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1. ACS Chemical Biology. 2025. doi:10.1021/acschembio.5c00112

BibTeX
@article{Soday2025,
  author = {Soday, Lior and Seripracharat, Chotima and Gray, Janine L and Luz, André F S and Howard, Ryan T and Singh, Ravi and Burden, Thomas J and Bernardini, Erika and Mateus-Pinheiro, Miguel and Petersen, Jens and Gunnarsson, Anders and Gunnarsson, Jenny and Aagaard, Anna and Sjögren, Tove and Maslen, Sarah and Bartlett, Edward J and Iles, Abigail F and Smith, David M and Scott, James S and Skehel, Mark and Davis, Andrew M and Ressurreição, Ana S and Moreira, Rui and Rodrigues, Cecília M P and Shenoy, Avinash R and Tate, Edward W},
  title = {Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1},
  journal = {ACS Chemical Biology},
  year = {2025},
  doi = {10.1021/acschembio.5c00112}
}
Kostenlos starten →